A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial (vol 261, pg 2101, 2014)

dc.contributor[Ziemssen, Tjalf] Neurol Univ Klin Klinikum Carl Gustav Carus, D-01307 Dresden, Germany; [Bajenaru, Ovidiu A.] Carol Davila Univ Med & Pharm, Bucharest, Romania; [Carra, Adriana] Hosp Britanico Buenos Aires, Buenos Aires, DF, Argentina; [de Klippel, Nina] Virga Jessaziekenhuis, Hasselt, Belgium; [de Sa, Joao Correia] Hosp Santa Maria, Lisbon, Portugal; [Edland, Astrid] Cent Hosp Buskerud, Drammen, Norway; [Frederiksen, Jette L.] Univ Copenhagen, Glostrup Hosp, Glostrup, Denmark; [Heinzlef, Olivier] Tenon Hosp, Paris, France; [Karageorgiou, Klimentini E.] Gen Hosp Athens, Athens, Greece; [Landtblom, Anne-Marie] Linkoping Univ, Dept Neurol, Linkoping, Sweden; [Landtblom, Anne-Marie] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden; [Landtblom, Anne-Marie] Linkoping Univ, Dept Med Specialists, Motala, Sweden; [Landtblom, Anne-Marie] Linkoping Univ, Dept Med & Hlth Sci, Motala, Sweden; [Macias Islas, Miguel A.] Cent Univ Guadalajara, Guadalajara, Jalisco, Mexico; [Tubridy, Niall] Dublin Univ, Sch Med & Med Sci, Dublin, Ireland; [Gilgun-Sherki, Yossi] Teva Pharmaceut Ind Ltd, Petah Tiqwa, Israel
dc.creatorZiemssen, T
dc.creatorBajenaru, OA
dc.creatorCarra, A
dc.creatorde Klippel, N
dc.creatorde Sa, JC
dc.creatorEdland, A
dc.creatorFrederiksen, JL
dc.creatorHeinzlef, O
dc.creatorKarageorgiou, KE
dc.creatorDelgado, RHL
dc.creatorLandtblom, AM
dc.creatorIslas, MAM
dc.creatorTubridy, N
dc.creatorGilgun-Sherki, Y
dc.date.accessioned2015-09-15T19:20:32Z
dc.date.accessioned2022-11-02T14:53:31Z
dc.date.available2015-09-15T19:20:32Z
dc.date.available2022-11-02T14:53:31Z
dc.date.created2015-09-15T19:20:32Z
dc.date.issued2015
dc.identifier0340-5354
dc.identifierhttp://hdl.handle.net/20.500.12104/45817
dc.identifier10.1007/s00415-014-7565-7
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5005839
dc.languageEnglish
dc.publisherSPRINGER HEIDELBERG
dc.relationWOS
dc.relationJOURNAL OF NEUROLOGY
dc.relation262
dc.relation1
dc.relation248
dc.relation248
dc.titleA 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial (vol 261, pg 2101, 2014)
dc.typeCorrection


Este ítem pertenece a la siguiente institución